The Center for Biosimilars recaps the top 5 articles for the week of November 27.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 27.
Number 5: The World Health Organization has a released a new report that estimates that 1 in 10 drugs worldwide is either falsified or substandard, leading to unnecessary deaths and increased costs to patients and health systems.
Number 4: German drug maker Formycon projects that its biosimilar challenger to Lucentis will be launched in the US market in 2020.
Number 3: The FDA has begun to add 4-letter suffixes, devoid of meaning, to the nonproprietary names of newly approved biologics.
Number 2: Contributor Brian Lehman explains the potential impact of CMS’ proposed rule that would treat biosimilars as generic drugs for the purpose of cost-sharing under Medicare Part D.
Number 1: The FDA has approved Mylan and Biocon’s trastuzumab biosimilar, referenced on Herceptin.
Finally, last week, our e-newsletter asked whether you think that innovative device design will play a role in reference product sponsors’ defense strategies against biosimilar competition. To see results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.